Evidence map›Paper›PMID 41924606›Full record

ReviewFrontiers in oncology2026

Review of advances in CAR-T therapies in malignant hematology.

Neda Amirmokhtari, Forat Lutfi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Neda AmirmokhtariHematologic malignancies and cellular therapy, The University of Kansas Hospital - Westwood Medical Pavilion, Westwood, KS, United States.
Forat LutfiHematologic malignancies and cellular therapy, The University of Kansas Hospital - Westwood Medical Pavilion, Westwood, KS, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There have been numerous advancements in immune cell effector therapies in the malignant hematology space. This review article explores the pivotal studies that led to the approval of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and highlights available associated long-term and real-world data. It also examines the mechanisms of resistance and potential novel therapies to overcome these mechanisms.

Indexed as

acute lymphoblastic B-cell leukemiaadverse eventsAESanti-CD19 CAR-T therapyauto-CARTslymphoma - diagnosis

Identifiers

PMID41924606
PMCPMC13035724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.